Genomic evolution and the impact of SLIT2 mutation in relapsed intrahepatic cholangiocarcinoma

Abstract Background and Aims Intrahepatic cholangiocarcinoma (ICC) is aggressive and has high rates of relapse, conferring poor long‐term survival after curative resection. Little is known about the genomic evolution that occurs during ICC relapse. Approach and Results We conducted whole‐exome sequencing of 30 paired primary and relapsed tumors from 10 patients with ICC who received curative resection. We sought to identify frequently altered genes, infer tumor subclonal architectures, and track genomic evolution from primary to relapsed tumors. We examined functional effects and the mechanism of action of SLIT2 , a gene specifically mutated in relapsed tumors, on tumor growth and metastasis and the tumor microenvironment. Our results indicated that relapsed ICCs were genetically derived from intrahepatic dissemination of primary tumors. However, they acquired additional mutations while maintaining most drivers, such as TP53 and IDH1 . Multiregion sequencing suggested polyclonal seeding of ICC dissemination. Four of 10 relapsed ICCs acquired SLIT2 mutations that were not present in the corresponding primary tumors. Validation in an expanded sample revealed SLIT2 mutations in 2.3% (1/44) of primary ICCs and 29.5% (13/44) of relapsed ICCs. Biofunctional investigations revealed that inactivating mutation of SLIT2 resulted in activation of PI3K–Akt signaling in ICC cells, directly enhanced neutrophil chemotaxis, mediated tumor‐associated neutrophil infiltration, and contributed to ICC growth and metastasis. Conclusions We characterized genomic evolution during ICC relapse and identified SLIT2 as a driver of tumor dissemination and tumor‐associated neutrophil infiltration.